Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
May 20, 2019
Fact of the Week: Chinese Patents Received 90 Percent as Many Citations as Other Countries From 2001 to 2009, but only 32 Percent as Many Foreign Citations
China’s patent output has grown dramatically in recent years, both in terms of the volume of patents submitted for international protection under the Patent Cooperation Treaty (PCT) and in terms of the number of citations those patents receive, a standard measure of a patent’s importance. New research breaking down the sources of those citations raises significant doubts about whether the growth in Chinese patent citations is as meaningful as it appears.
May 16, 2019
Testimony Before the House Oversight Committee on Drug Prices, Intellectual Property, and Biomedical Innovation
In testimony before the House Oversight Committee, Stephen Ezell explained why the United States leads the world in life-sciences innovation; how the public and private sectors contribute; why innovation depends on the ability to generate revenues; the consequences of price controls; and how best to control health-care costs.
April 22, 2019
Debates over drug pricing often consider the impacts on health and innovation, but rarely examine the costs those drugs offset. According to new research examining drug releases for 67 diseases across 15 countries in the three decades from 1982 to 2015, these offsets are dramatic.
April 15, 2019
Seven case studies showcase how IP rights are enabling innovators in Latin America to help solve some of the greatest global health challenges.
April 9, 2019
America’s ability to compete globally in biomedical innovation is being threatened.
March 25, 2019
NIH funding is critical to improving health outcomes and reducing the societal costs of illnesses. Congress should increase the NIH budget and then maintain regular, steady increases.
March 7, 2019
America’s ascendance as the world’s leader in life-sciences innovation has been the result of thoughtful, intentional public policies, including robust funding for the National Institutes of Health
March 4, 2019
Misusing the “march-in right” provision of the Bayh-Dole Act could negatively impact U.S. life-sciences innovation and result in fewer new drugs.
February 25, 2019
A new study has sought to quantify this impact, tracking the availability of drugs released after 1981 that are designed to treat 66 diseases across 27 countries.
December 31, 2018
Comments to the Centers for Medicare & Medicaid Services on an International Pricing Index Model for Medicare Part B Drugs
Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.